Taro Kishi

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 90

Top Topics

Randomized Controlled Trial

Systematic Review

Major Depressive Disorder

Top Venues

Neuropsychopharmacology reports

Psychiatry and clinical neurosciences

Bipolar disorders

Molecular psychiatry

This page only lists publications with an associated author ORCID identifier.

Publications

Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Jonas Wilkening, Roberto Goya-Maldonado, Martin Tik, Nolan R Williams, Shinsuke Kito, Masashi Ikeda
Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis. Molecular psychiatry (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa
Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports (2024)
Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa
Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports 44 (2) (2024)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Michinori Koebis, Michiko Sugawara, Yuka Kawatsu, Takehiro Taninaga, Masashi Ikeda
Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. Translational psychiatry 14 (1) (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa
Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports 44 (2) (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Tadafumi Kato, Kazuyoshi Ogasawara, Keisuke Motomura, Masaki Kato, Teruaki Tanaka, Yoshikazu Takaesu, Shintaro Nio, Taro Kishi, Mirai So, Kiyotaka Nemoto, Eiji Suzuki, Koichiro Watanabe, Koji Matsuo, null null, null null, null null
Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). Psychiatry and clinical neurosciences (2024)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences 78 (4) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa
Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports 44 (2) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Yasuhiro Iwama, Yuji Sasagawa, Shuichi Hiraoka, Aya Kamei, Nakao Iwata
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
Repetitive transcranial magnetic stimulation for mania: A systematic review and meta-analysis. Bipolar disorders 25 (2) (2023)
Yupeng He, Masaaki Matsunaga, Yuanying Li, Taro Kishi, Shinichi Tanihara, Masashi Ikeda, Takahiro Tabuchi, Atsuhiko Ota
Classifying Schizophrenia Cases by Artificial Neural Network Using Japanese Web-Based Survey Data: Case-Control Study. JMIR formative research 7 (2023)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of antipsychotic transdermal patch for acute schizophrenia: a systematic review and meta-analysis. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Masaki Kato, Nakao Iwata
Safety profile of antidepressant for Japanese adults with major depressive disorder: a systematic review and network meta-analysis. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwata
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports 43 (1) (2023)
Taro Kishi, Leslie Citrome, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Acceptability of Antipsychotic Transdermal Patch for Acute Schizophrenia: A Systematic Review and Meta-analysis. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
Repetitive transcranial magnetic stimulation for mania: A systematic review and meta-analysis. Bipolar disorders (2023)
Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
Repetitive transcranial magnetic stimulation for mania: A systematic review and meta-analysis. Bipolar disorders 25 (2) (2023)
Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
Repetitive Transcranial Magnetic Stimulation for Mania: A Systematic Review and Meta-analysis. Bipolar disorders (2023)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Hikaru Hori, Masaki Kato, Nakao Iwata
Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports (2023)
Kenji Sakuma, Taro Kishi, Shohei Sanji, Ikuo Nomura, Masakazu Hatano, Makoto Okuya, Nakao Iwata
Phosphodiesterase type 5 inhibitors for the treatment of sexual dysfunction in males with major depressive disorder: A systematic review and meta-analysis. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Yasuhiro Iwama, Yuji Sasagawa, Shuichi Hiraoka, Aya Kamei, Nakao Iwata
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwata
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports 43 (1) (2023)
Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwata
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports 43 (1) (2023)
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Shinsuke Kito, Masashi Ikeda
Repetitive transcranial magnetic stimulation for bipolar depression: a systematic review and pairwise and network meta-analysis. Molecular psychiatry (2023)
Kenji Sakuma, Taro Kishi, Shohei Sanji, Ikuo Nomura, Masakazu Hatano, Makoto Okuya, Nakao Iwata
Phosphodiesterase type 5 inhibitors for the treatment of sexual dysfunction in males with major depressive disorder: A systematic review and meta-analysis. Psychiatry and clinical neurosciences (2023)
Taro Kishi, Hiroshi Nakamura, Tadafumi Kato, Nakao Iwata
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression. Neuropsychopharmacology reports (2023)
Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
Repetitive transcranial magnetic stimulation for mania: A systematic review and meta-analysis. Bipolar disorders 25 (2) (2023)
Taro Kishi, Hiroshi Nakamura, Nakao Iwata
Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test. Psychiatry and clinical neurosciences 76 (8) (2022)
Taro Kishi, Kenji Sakuma, Masashi Ikeda
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. Translational psychiatry 12 (1) (2022)
Taro Kishi, Kenji Sakuma, Masashi Ikeda
Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis. Translational psychiatry 12 (1) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Takeo Saito, Kyung Sue Hong, Chikashi Terao, Takuma Ashizawa, Masami Miyata, Satoshi Tanaka, Tetsufumi Kanazawa, Tadafumi Kato, Taro Kishi, Nakao Iwata
Differential genetic correlations across major psychiatric disorders between Eastern and Western countries. Psychiatry and clinical neurosciences (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry (2022)
Taro Kishi, Kenji Sakuma, Masashi Ikeda
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. Translational psychiatry 12 (1) (2022)
Kyung Sue Hong, Takeo Saito, Tetsufumi Kanazawa, Taro Kishi, Nakao Iwata
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania. Psychiatry and clinical neurosciences 76 (11) (2022)
Taro Kishi, Makoto Okuya, Kenji Sakuma, Yohei Otaka, Eiichi Saitoh, Nakao Iwata
Walking intervention and dietary guidance efficacy for overweight people with schizophrenia: An open-label 12-week study. PCN reports : psychiatry and clinical neurosciences 1 (4) (2022)
Taro Kishi, Kenji Sakuma, Masashi Ikeda
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. Translational psychiatry 12 (1) (2022)
Yupeng He, Ayako Tanaka, Taro Kishi, Yuanying Li, Masaaki Matsunaga, Shinichi Tanihara, Nakao Iwata, Atsuhiko Ota
Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review. Neuropsychopharmacology reports (2022)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Nakao Iwata
Lemborexant for insomnia in adults with psychiatric disorders: A 1-week, open-label study. PCN reports : psychiatry and clinical neurosciences 1 (3) (2022)
Taro Kishi, Hiromi Hayakawa, Yui Kawamoto, Yosuke Nakao, Tae Narita, Kazuhiro Nishimoto, Kenji Sakuma, Nakao Iwata
Levetiracetam for bipolar disorder: Consideration from a systematic review. Bipolar disorders (2022)
Taro Kishi, Kenji Sakuma, Masashi Ikeda
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. Translational psychiatry 12 (1) (2022)
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Makoto Okuya, Masakazu Hatano, Yuki Matsuda, Masashi Ikeda
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular psychiatry (2022)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Nakao Iwata
Lemborexant for insomnia in adults with psychiatric disorders: A 1-week, open-label study. PCN reports : psychiatry and clinical neurosciences 1 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Nakao Iwata
N-acetylcysteine for schizophrenia: A systematic review and meta-analysis. Psychiatry and clinical neurosciences (2022)
Taro Kishi, Makoto Okuya, Kenji Sakuma, Yohei Otaka, Eiichi Saitoh, Nakao Iwata
Walking intervention and dietary guidance efficacy for overweight people with schizophrenia: An open-label 12-week study. PCN reports : psychiatry and clinical neurosciences 1 (4) (2022)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Kyung Sue Hong, Nakao Iwata
Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. Bipolar disorders 23 (7) (2021)
Taro Kishi, Makoto Okuya, Kenji Sakuma, Yohei Otaka, Eiichi Saitoh, Nakao Iwata
Body composition in Japanese patients with psychiatric disorders: A cross-sectional study. Neuropsychopharmacology reports 41 (1) (2021)
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Makoto Okuya, Hiromi Hayakawa, Nakao Iwata
Observations on the results of a systematic review and network meta-analysis of double-blind randomized, placebo-controlled trials to examine early onset of response to pharmacological intervention for bipolar depression. Bipolar disorders (2021)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Masakazu Hatano, Nakao Iwata
Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. Neuropsychopharmacology reports 41 (3) (2021)
Taro Kishi, Hiroto Nishiyama, Yuki Kimura, Tomohiro Sadaka, Akihiro Terada, Yuki Tatsumi, Mizuna Wakahara, Nakao Iwata
Melatonin receptor agonists for bipolar mania: A systematic review and meta-analyses of double-blind randomized placebo-controlled trials. Bipolar disorders 23 (3) (2021)
Taro Kishi, Hiroshi Nakamura, Nakao Iwata
Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis. Psychopharmacology 238 (12) (2021)
Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun-Ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, Hideaki Tabuse, Shotatsu Koretsune, Hiroshi Terada, Haruko Terada, Toshifumi Kishimoto, Yuichiro Tsutsumi, Yoshiki Kanda, Kazutaka Ohi, Kanji Sekiyama
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry and clinical neurosciences (2021)
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Masakazu Hatano, Masashi Ikeda
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular psychiatry (2021)
Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata
Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacology reports (2021)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Satoru Esumi, Yasuhiko Hashimoto, Masakazu Hatano, Nobumi Miyake, Itaru Miura, Kazuo Mishima, Nakao Iwata
Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar disorders (2021)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Masakazu Hatano, Nakao Iwata
Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia. Psychiatry and clinical neurosciences (2021)
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Kazuo Mishima, Masashi Ikeda
Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Molecular psychiatry 26 (8) (2020)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Nakao Iwata
Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. Psychiatry and clinical neurosciences 74 (5) (2020)
Taro Kishi, Tadashi Nosaka, Kenji Sakuma, Makoto Okuya, Nakao Iwata
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports 40 (3) (2020)
Taro Kishi, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Kazuo Mishima, Nakao Iwata
Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis. Psychological medicine 51 (15) (2020)
Taro Kishi, Reiji Yoshimura, Kenji Sakuma, Makoto Okuya, Nakao Iwata
Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports 40 (4) (2020)
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Nakao Iwata
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology 237 (5) (2020)
Naomichi Okamoto, Keita Watanabe, LeHoa Ngyuyen, Atsuko Ikenouchi, Taro Kishi, Masashi Ikeda, Shingo Kakeda, Yukunori Korogi, Reiji Yoshimura
Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study. Neuropsychiatric disease and treatment 16 (2020)
Taro Kishi, Nobumi Miyake, Makoto Okuya, Kenji Sakuma, Nakao Iwata
N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology 237 (11) (2020)
Taro Kishi, Kenji Sakuma, Makoto Okuya, Kohei Ninomiya, Kazuto Oya, Momoko Kubo, Yuki Matsui, Ikuo Nomura, Yuji Okuyama, Shinji Matsunaga, Nakao Iwata
Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study. Neuropsychopharmacology reports 39 (3) (2019)
Kazuto Oya, Kenji Sakuma, Satoru Esumi, Yasuhiko Hashimoto, Masakazu Hatano, Yuki Matsuda, Yuki Matsui, Nobumi Miyake, Ikuo Nomura, Makoto Okuya, Nakao Iwata, Masaki Kato, Ryota Hashimoto, Kazuo Mishima, Norio Watanabe, Taro Kishi
Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology reports 39 (3) (2019)
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Nakao Iwata
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. Neuropsychopharmacology reports 39 (3) (2019)
Kenji Sakuma, Shinji Matsunaga, Ikuo Nomura, Makoto Okuya, Taro Kishi, Nakao Iwata
Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology 235 (8) (2018)
Kenji Sakuma, Taro Kishi, Nakao Iwata
Response to the Letter from Dr. Jacob Peedicayil. Psychopharmacology 236 (4) (2018)
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Nakao Iwata
Response to the letter from Dr. Veerman and colleagues. Psychopharmacology 234 (23-24) (2017)